Acute myelomonocytic leukemia and the French-American-British classification

Acta Haematologica
D Huhn, L Twardzik

Abstract

39 patients suffering from different subtypes of monocytic (M 5) and myelomonocytic (M 4) leukemia were analyzed retrospectively. In 8 cases a 'transitional myelomonocytic variant' was diagnosed; the leukemic cell in these patients is marked by morphological and cytochemical signs of monocytic and granulocytic precursors. As the correct diagnosis of this special subtype may be difficult, its place within the French-American-British (FAB) classification will be discussed.

Citations

Jan 1, 1988·Leukemia Research·A BrizardJ Tanzer
Apr 5, 2003·Immunopharmacology and Immunotoxicology·L PassantinoG Ranieri
Apr 9, 2010·International Journal of Rheumatic Diseases·Nambiar Veettil JayachandranGumdal Narsimulu
Aug 1, 1991·American Journal of Hematology·J RoyD Weisdorf
Oct 16, 2012·The American Journal of Medicine·Amishi DesaiBurke A Cunha
Nov 1, 1984·British Journal of Haematology·D W MilliganC S Scott
Mar 1, 1986·Veterinary Pathology·M M ChristopherD W Hayden
Jan 1, 1986·Scandinavian Journal of Haematology. Supplementum·B Frisch, R Bartl

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.